Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
CALCIJEX®, 1-25-dihydroxycholecalciferol
Vitamin D3 Metabolite
Original Date: 
August 2005
Revised Date: 
September 2011
  • Management of hypocalcemia in patients undergoing chronic renal hemodialysis
  • Treatment of hypocalcemic tetany in premature infants
Reconstitution and Stability: 
  • Available as 1 mcg/mL injection
  • Store at room temperature
  • Protect from light and excessive heat in original container

- Solutions Compatible: D5W, NS, Sterile Water for Injection

- Additives/Above Cassette Compatible: no information

- Y-site Compatible: no information

- Incompatible: do not mix with any other drug


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct

Usual dilution: 1 mcg/mL
Infusion rate: over 15 seconds or through catheter at end of hemodialysis

IV Intermittent Infusion YES
Usual dilution: 1 mcg/mL
Infusion time: 15 minutes
IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • Hemodialysis patients: 0.01-0.05 mcg/kg/dose three times weekly


  • Hemodialysis patients: 0.5 mcg (0.1 mcg/kg) IV 3 times/week; may increase dosage by 0.25 - 0.5 mcg increments at 2-4 week intervals until optimal response is achieved. [Range 0.5-3 mcg]
Potential hazards of parenteral administration: 
  • Mild pain at site of injection    
  • Hypercalcemia
  • Vitamin D intoxication
  • Excessive dosage induces hypercalcemia which can lead to generalized vascular calcification, nephrocalcinosis, calcifications of cornea or other soft tissues
  • Early and late signs of vitamin D intoxication and hypercalcemia:
    - Early:  weakness, headache, somnolence, nausea, vomiting, thirst,
    dry mouth, constipation, muscle and bone pain, metallic taste,
    cardiac arrhythmias

    Late: polyuria, polydipsia, anorexia, conjunctivitis, nocturia, pancreatitis,
    photophobia, rhinorrhea, pruritus, hyperthermia, decreased libido,
    ectopic calcification, cardiac arrhythmias and hypertension

  • Treatment of hypercalcemia includes discontinuation of calcitriol, institution of a low calcium diet and withdrawal of calcium supplementation
  • Do not use in combination with magnesium containing antacids, as hypermagnesemia may develop       
  • Monitor serum calcium and phosphorus levels

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.